MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-GJ-01-0030699
Market Cap
₹24.00 Cr
MIL · BSE
Share Price
₹24.99
+4.12% today
Revenue
₹84.08 Cr
FY 2025-26 · -12.4% YoY
EBITDA
₹2.97 Cr
Margin 3.5%
Net Profit
−₹3.21 Cr
FY 2025-26 · -163.6% YoY
Authorised capital
₹20 Cr
Registered with MCA
Paid-up capital
₹10 Cr
Issued & subscribed
Open charges
₹15.5 Cr
Satisfied ₹2.05 Cr
About Medico Intercontinental Limited
Data last updated:
Medico Intercontinental Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 14 August 1984 and has been in existence for over 42 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24100GJ1984PLC111413. Its GSTIN is 24AAACI1860R1ZB (Gujarat). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 539938.
The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹10 Cr. It was formerly known as Medico Mediserve India Limited and Medico Mediserve Trading Limited. It is led by directors including Samir Dilipkumar Shah (Managing Director) and Tanvi Samirbhai Shah.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Ahmedabad, Gujarat.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹84.08 Cr, a decline of 12.4% compared to the previous year. For the same year it recorded a net loss of ₹3.21 Cr (net margin -3.8%) and EBITDA of ₹2.97 Cr (EBITDA margin 3.5%). The net worth stands at ₹46.89 Cr (down 6.4% YoY). Total assets are valued at ₹99.72 Cr (up 47.1% YoY).
The company has about 17 employees on its provident fund (EPFO) records. Its group structure includes 4 subsidiaries.
The company is associated with 1 brand: Medico Intercontinental. As per MCA filings, the company has open charges of ₹15.5 Cr and satisfied charges of ₹2.05 Cr on record. Court records list 14 cases involving the company, including 13 filed by the company and 1 filed against it; 4 cases are pending. The company has 69 deals on record (66 market trades, 2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹23.93 Cr; the latest was in June 2026. Its 5 peer companies in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 3 larger and 2 smaller; the largest is Visa Pharmaceuticals Private Limited with revenue of ₹98.08 Cr. The company has 18 MSME Form 1 returns on record between 2019 and 2024, listing 4,827 overdue payments to 81 micro and small suppliers.
Medico Intercontinental Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-01-0030699). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medicointercontinental.com.
Company details
CIN L24100GJ1984PLC111413
Registration Number 111413
Incorporation Date 14 August 1984
ROC Ahmedabad
Listing Status Listed - Listed on BSE (539938)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-GJ-01-0030699
Name history
Medico Intercontinental has undergone 3 name changes throughout its history. The company was previously known as Medico Mediserve India Limited, Medico Mediserve Trading Limited, and Intercontinental Leasing And Finance Company Limited. The current legal name is Medico Intercontinental Limited.
| Company Name | Status |
|---|---|
| Medico Intercontinental Limited | Current |
| Medico Mediserve India Limited | Previous |
| Medico Mediserve Trading Limited | Previous |
| Intercontinental Leasing And Finance Company Limited | Previous |
CIN history
Medico Intercontinental has 5 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24100GJ1984PLC111413, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24100GJ1984PLC111413 | Current |
| L24100MH1984PLC269707 | Previous |
| L67120DL1984PLC018974 | Previous |
| U67120DL1984PLC018974 | Previous |
| L67120MH1984PLC269707 | Previous |
| L51100MH1984PLC269707 | Previous |
Key People
Dilipkumar Bhogilal Shah Ceo Samir Dilipkumar Shah Managing Director Jay Sharadkumar Shah Cfo Recognitions & Rankings of Medico Intercontinental
Contact details
Medico Intercontinental Limited's registered office is in Ahmedabad, Gujarat. Its website is medicointercontinental.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address1 – 5th Floor Adit Raj Arcade Nr Karma Shreshtha Tower 100 Ft Rd Sat, Ellite, Ahmedabad, Gujarat, India – 380015
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Medico Intercontinental Limited, buy the company report.
Comprehensive company report
Medico Intercontinental Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Medico Intercontinental operates one associated brand: Medico Intercontinental. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Biopharmaceuticals, health devices, and therapies in healthcare sectors. | medicointercontinental.com |
Business activity
The main business activity of Medico Intercontinental is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Medico Intercontinental Limited, buy the company report.
Financials of Medico Intercontinental Limited
FY 2025-26 filings availableMedico Intercontinental Limited reported revenue of ₹84.08 Cr (down 12.4% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹84.08 Cr
-12.4% YoY
EBITDA
₹2.97 Cr
-64.7% YoY
Profit After Tax
−₹3.21 Cr
-163.6% YoY
Net Worth
₹46.89 Cr
-6.4% YoY
Total Assets
₹99.72 Cr
+47.1% YoY
Total Debt
₹67.12 Cr
+296.7% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 84.08 | 96.02 | 71.36 | 76.23 | 74.26 | 69.74 | 81.96 |
| Revenue growth | -12.4% | +34.6% | -6.4% | +2.7% | +6.5% | -14.9% | - |
| EBITDA | 2.97 | 8.41 | 5.81 | 5.28 | 5.00 | 4.77 | 4.35 |
| EBITDA margin | +3.5% | +8.8% | +8.1% | +6.9% | +6.7% | +6.8% | +5.3% |
| Profit before tax | (9.35) | 6.96 | 5.42 | 4.97 | 4.22 | 3.53 | 3.20 |
| Net profit | (3.21) | 5.05 | 3.93 | 3.63 | 3.09 | 2.58 | 2.36 |
| Net profit margin | -3.8% | +5.3% | +5.5% | +4.8% | +4.2% | +3.7% | +2.9% |
| EPS (₹) | (3.20) | 5.06 | 3.95 | 3.61 | 9.54 | 7.93 | 7.25 |
| Balance sheet | |||||||
| Total assets | 99.72 | 67.78 | 50.03 | 46.02 | 21.37 | 18.85 | 20.02 |
| Net worth | 46.89 | 50.09 | 45.03 | 41.19 | 12.64 | 9.54 | 6.36 |
| Total debt | 67.12 | 16.92 | 4.86 | 4.72 | 8.73 | 9.31 | 13.66 |
| Cash & bank | 5.96 | 2.24 | 3.37 | 6.79 | 1.87 | 0.51 | 0.78 |
| Net working capital | 44.54 | 45.78 | 32.49 | 36.85 | 17.71 | 16.35 | 18.03 |
| Cash flow | |||||||
| Cash from operations | 17.08 | (6.26) | 5.58 | (10.10) | 3.85 | 5.82 | (13.82) |
| Cash from investing | 2.20 | (4.93) | (8.54) | (5.38) | (1.30) | (0.94) | 0.00 |
| Cash from financing | (15.56) | 10.07 | (0.46) | 20.41 | (1.20) | (5.14) | 13.42 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.71 | 22.49 | 19.85 | 20.40 | 21.35 | 21.16 | 18.43 | 36.45 |
| Revenue growth (YoY) | -3.0% | +6.3% | +7.7% | -44.0% | +10.7% | - | - | - |
| Other income | 0.13 | 0.11 | 0.34 | 0.55 | 0.29 | 0.11 | 0.13 | 0.10 |
| EBITDA | (0.69) | 1.61 | 1.59 | (0.88) | 0.67 | 1.94 | 1.90 | 2.71 |
| EBITDA margin | -3.3% | +7.2% | +8.0% | -4.3% | +3.1% | +9.2% | +10.3% | +7.4% |
| Depreciation | 1.21 | 1.43 | 1.43 | 1.95 | 0.62 | 0.28 | 0.23 | 0.20 |
| Interest | 1.91 | 1.85 | 1.90 | 2.06 | 2.36 | 0.30 | 0.24 | 0.28 |
| Profit before tax | (3.68) | (1.56) | (1.40) | (4.34) | (2.02) | 1.47 | 1.56 | 2.33 |
| Tax | 0.38 | 0.80 | 0.28 | 0.20 | 0.48 | 0.33 | 0.43 | 0.69 |
| Net profit | (4.06) | (2.36) | (1.68) | (4.54) | (2.50) | 1.14 | 1.13 | 1.64 |
| EPS (₹) | (1.45) | (0.65) | (0.22) | (1.65) | (0.68) | 1.17 | 1.17 | 1.63 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 54.46 | 67.13 | 44.04 | 48.88 | 39.25 | 41.02 | 46.93 |
| Revenue growth | -18.9% | +52.4% | -9.9% | +24.5% | -4.3% | -12.6% | - |
| EBITDA | 3.13 | 4.29 | 2.61 | 2.48 | 2.27 | 2.34 | 2.19 |
| EBITDA margin | +5.8% | +6.4% | +5.9% | +5.1% | +5.8% | +5.7% | +4.7% |
| Profit before tax | 3.12 | 3.57 | 2.63 | 2.36 | 1.83 | 1.66 | 1.53 |
| Net profit | 2.19 | 2.57 | 1.91 | 1.69 | 1.31 | 1.20 | 1.11 |
| Net profit margin | +4.0% | +3.8% | +4.3% | +3.5% | +3.3% | +2.9% | +2.4% |
| EPS (₹) | 2.18 | 2.57 | 1.90 | 1.70 | 4.04 | 3.68 | 3.44 |
| Balance sheet | |||||||
| Total assets | 57.15 | 52.26 | 37.13 | 36.62 | 13.86 | 11.16 | 13.70 |
| Net worth | 40.85 | 38.66 | 36.10 | 34.30 | 7.65 | 6.34 | 5.15 |
| Total debt | 16.15 | 13.22 | 0.96 | 2.27 | 6.21 | 4.81 | 8.56 |
| Cash & bank | 2.16 | 1.42 | 2.41 | 4.95 | 1.29 | 0.12 | 0.14 |
| Net working capital | 16.88 | 30.36 | 19.71 | 26.00 | 8.49 | 6.55 | 10.00 |
| Cash flow | |||||||
| Cash from operations | 15.43 | (6.78) | 5.73 | (11.95) | 1.10 | 5.44 | (6.55) |
| Cash from investing | 8.25 | (4.78) | (6.65) | (5.02) | (0.80) | (0.94) | (3.68) |
| Cash from financing | (22.94) | 10.57 | (1.63) | 20.63 | 0.87 | (4.51) | 9.22 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.33 | 15.82 | 12.75 | 12.42 | 13.47 | 15.24 | 11.43 | 28.94 |
| Revenue growth (YoY) | +6.4% | +3.8% | +11.6% | -57.1% | +16.9% | - | - | - |
| Other income | 0.91 | 0.73 | 0.79 | 0.58 | 0.24 | 0.13 | 0.17 | 0.10 |
| Total expenses | 13.84 | 15.27 | 12.14 | 11.56 | 12.36 | 14.24 | 10.51 | 27.26 |
| EBITDA | 0.49 | 0.55 | 0.61 | 0.86 | 1.11 | 1.00 | 0.92 | 1.68 |
| EBITDA margin | +3.4% | +3.5% | +4.8% | +6.9% | +8.2% | +6.6% | +8.0% | +5.8% |
| Depreciation | 0.11 | 0.16 | 0.17 | 0.19 | 0.18 | 0.21 | 0.17 | 0.15 |
| Interest | 0.48 | 0.40 | 0.39 | 0.45 | 0.44 | 0.23 | 0.17 | 0.18 |
| Profit before tax | 0.81 | 0.72 | 0.84 | 0.80 | 0.73 | 0.69 | 0.75 | 1.45 |
| Tax | 0.21 | 0.30 | 0.24 | 0.22 | 0.18 | 0.16 | 0.21 | 0.46 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 27 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.71 | 22.49 | 19.85 | 20.40 | 21.35 | 21.16 | 18.43 | 36.45 |
| Revenue growth (YoY) | -3.0% | +6.3% | +7.7% | -44.0% | +10.7% | - | - | - |
| Other income | 0.13 | 0.11 | 0.34 | 0.55 | 0.29 | 0.11 | 0.13 | 0.10 |
| EBITDA | (0.69) | 1.61 | 1.59 | (0.88) | 0.67 | 1.94 | 1.90 | 2.71 |
| EBITDA margin | -3.3% | +7.2% | +8.0% | -4.3% | +3.1% | +9.2% | +10.3% | +7.4% |
| Depreciation | 1.21 | 1.43 | 1.43 | 1.95 | 0.62 | 0.28 | 0.23 | 0.20 |
| Interest | 1.91 | 1.85 | 1.90 | 2.06 | 2.36 | 0.30 | 0.24 | 0.28 |
| Profit before tax | (3.68) | (1.56) | (1.40) | (4.34) | (2.02) | 1.47 | 1.56 | 2.33 |
| Tax | 0.38 | 0.80 | 0.28 | 0.20 | 0.48 | 0.33 | 0.43 | 0.69 |
| Net profit | (4.06) | (2.36) | (1.68) | (4.54) | (2.50) | 1.14 | 1.13 | 1.64 |
| EPS (₹) | (1.45) | (0.65) | (0.22) | (1.65) | (0.68) | 1.17 | 1.17 | 1.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 84.08 | 96.02 | 71.36 | 76.23 | 74.26 | 69.74 | 81.96 |
| Revenue growth | -12.4% | +34.6% | -6.4% | +2.7% | +6.5% | -14.9% | - |
| Other income | 1.27 | 0.36 | 0.40 | 0.51 | 0.31 | 0.18 | 0.05 |
| Total expenses | 81.11 | 87.61 | 65.55 | 70.95 | 69.26 | 64.97 | 77.61 |
| Employee cost | 0.00 | 3.79 | 2.97 | 2.47 | 1.75 | 1.81 | 3.01 |
| EBITDA | 2.97 | 8.41 | 5.81 | 5.28 | 5.00 | 4.77 | 4.35 |
| EBITDA margin | +3.5% | +8.8% | +8.1% | +6.9% | +6.7% | +6.8% | +5.3% |
| Depreciation | 5.43 | 0.81 | 0.29 | 0.20 | 0.21 | 0.14 | 0.10 |
| Interest | 8.16 | 1.00 | 0.50 | 0.62 | 0.88 | 1.28 | 1.10 |
| Profit before tax | (9.35) | 6.96 | 5.42 | 4.97 | 4.22 | 3.53 | 3.20 |
| Tax | 1.75 | 1.92 | 1.49 | 1.34 | 1.13 | 0.95 | 0.84 |
| Net profit | (3.21) | 5.05 | 3.93 | 3.63 | 3.09 | 2.58 | 2.36 |
| Net profit margin | -3.8% | +5.3% | +5.5% | +4.8% | +4.2% | +3.7% | +2.9% |
| EPS (₹) | (3.20) | 5.06 | 3.95 | 3.61 | 9.54 | 7.93 | 7.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.00 | 10.00 | 10.00 | 10.00 | 3.25 | 3.25 | 3.25 |
| Reserves & surplus | 36.89 | 40.09 | 35.03 | 31.19 | 9.39 | 6.29 | 3.11 |
| Shareholders' funds (net worth) | 46.89 | 50.09 | 45.03 | 41.19 | 12.64 | 9.54 | 6.36 |
| Minority interest | (14.62) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 45.68 | 16.49 | 4.44 | 4.40 | 7.58 | 6.16 | 8.38 |
| Unsecured loans | 21.44 | 0.43 | 0.42 | 0.32 | 1.15 | 3.15 | 5.28 |
| Total debt | 67.12 | 16.92 | 4.86 | 4.72 | 8.73 | 9.31 | 13.66 |
| Total liabilities | 99.72 | 67.78 | 50.03 | 46.02 | 21.37 | 18.85 | 20.02 |
| Assets | |||||||
| Gross block | 61.77 | 11.18 | 5.28 | 4.04 | 3.62 | 3.41 | 2.61 |
| Net block | 51.03 | 8.64 | 3.52 | 2.57 | 2.35 | 2.35 | 1.69 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 2.30 | 3.01 | 0.02 | 0.02 | 0.01 | 0.16 | 0.00 |
| Inventories | 14.93 | 8.52 | 10.44 | 8.88 | 7.88 | 9.11 | 8.68 |
| Sundry debtors | 27.42 | 32.33 | 23.21 | 32.85 | 17.14 | 17.98 | 22.77 |
| Cash & bank balances | 5.96 | 2.24 | 3.37 | 6.79 | 1.87 | 0.51 | 0.78 |
| Loans & advances | 12.93 | 11.71 | 1.48 | 1.19 | 1.36 | 0.52 | 1.80 |
| Total current assets | 61.24 | 54.80 | 38.50 | 49.71 | 28.25 | 28.12 | 34.03 |
| Total current liabilities | 16.70 | 9.02 | 6.01 | 12.86 | 10.54 | 11.77 | 16.00 |
| Net working capital | 44.54 | 45.78 | 32.49 | 36.85 | 17.71 | 16.35 | 18.03 |
| Total assets | 99.72 | 67.78 | 50.03 | 46.02 | 21.37 | 18.85 | 20.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.24 | 3.37 | 6.79 | 1.87 | 0.51 | 0.78 | 1.18 |
| Net cash from operating activities | 17.08 | (6.26) | 5.58 | (10.10) | 3.85 | 5.82 | (13.82) |
| Net cash from investing activities | 2.20 | (4.93) | (8.54) | (5.38) | (1.30) | (0.94) | 0.00 |
| Net cash from financing activities | (15.56) | 10.07 | (0.46) | 20.41 | (1.20) | (5.14) | 13.42 |
| Net change in cash | 3.72 | (1.12) | (3.42) | 4.92 | 1.35 | (0.26) | (0.40) |
| Closing cash | 5.96 | 2.24 | 3.37 | 6.79 | 1.87 | 0.51 | 0.78 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -12.4% | +34.6% | -6.4% | +2.7% | +6.5% | -14.9% | - |
| EBITDA growth | -64.7% | +44.8% | +10.0% | +5.6% | +4.8% | +9.7% | - |
| PBT growth | - | +28.4% | +9.1% | +17.8% | +19.6% | +10.3% | +220.0% |
| Net income growth | -163.6% | +28.5% | +8.3% | +17.5% | +19.8% | +9.3% | - |
| Revenue CAGR (3Y) | +3.3% | +8.9% | +0.8% | -2.4% | +95.4% | - | - |
| EBITDA CAGR (3Y) | -17.5% | +18.9% | +6.8% | +6.7% | +97.4% | - | - |
| Profitability & leverage | |||||||
| Net income margin | -13.2% | +5.3% | +5.5% | +4.8% | +4.2% | +3.7% | +2.9% |
| Return on capital employed | - | +13.7% | +12.4% | +16.5% | +25.4% | +24.8% | +35.7% |
| Return on net worth | - | +10.8% | +9.2% | +13.4% | +28.0% | +32.5% | +45.6% |
| Debt / equity | - | 0.23 | 0.11 | 0.25 | 0.81 | 1.44 | 1.33 |
| Long-term debt / equity | - | 0.02 | 0.02 | 0.05 | 0.30 | 1.09 | 1.27 |
| Interest cover | -331.71 | 13.16 | 9.06 | 12.20 | 18.37 | 27.65 | 25.88 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 11.62 | 15.31 | 19.90 | 21.13 | 23.17 | 62.56 |
| Inventory turnover | - | 9.76 | 7.39 | 9.10 | 8.74 | 7.84 | 17.61 |
| Debtors turnover | - | 3.43 | 2.55 | 3.05 | 4.23 | 3.42 | 5.61 |
| EPS (₹) | (3.20) | 5.06 | 3.95 | 3.61 | 9.54 | 7.93 | 7.25 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 48.65 | 45.03 | 41.19 | 38.89 | 29.35 | 19.58 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.33 | 15.82 | 12.75 | 12.42 | 13.47 | 15.24 | 11.43 | 28.94 |
| Revenue growth (YoY) | +6.4% | +3.8% | +11.6% | -57.1% | +16.9% | - | - | - |
| Other income | 0.91 | 0.73 | 0.79 | 0.58 | 0.24 | 0.13 | 0.17 | 0.10 |
| Total expenses | 13.84 | 15.27 | 12.14 | 11.56 | 12.36 | 14.24 | 10.51 | 27.26 |
| EBITDA | 0.49 | 0.55 | 0.61 | 0.86 | 1.11 | 1.00 | 0.92 | 1.68 |
| EBITDA margin | +3.4% | +3.5% | +4.8% | +6.9% | +8.2% | +6.6% | +8.0% | +5.8% |
| Depreciation | 0.11 | 0.16 | 0.17 | 0.19 | 0.18 | 0.21 | 0.17 | 0.15 |
| Interest | 0.48 | 0.40 | 0.39 | 0.45 | 0.44 | 0.23 | 0.17 | 0.18 |
| Profit before tax | 0.81 | 0.72 | 0.84 | 0.80 | 0.73 | 0.69 | 0.75 | 1.45 |
| Tax | 0.21 | 0.30 | 0.24 | 0.22 | 0.18 | 0.16 | 0.21 | 0.46 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 54.46 | 67.13 | 44.04 | 48.88 | 39.25 | 41.02 | 46.93 |
| Revenue growth | -18.9% | +52.4% | -9.9% | +24.5% | -4.3% | -12.6% | - |
| Other income | 2.35 | 0.51 | 0.42 | 0.34 | 0.18 | 0.16 | 0.02 |
| Total expenses | 51.33 | 62.84 | 41.43 | 46.40 | 36.98 | 38.68 | 44.74 |
| Employee cost | 0.00 | 1.14 | 0.99 | 0.96 | 0.79 | 0.74 | 0.87 |
| EBITDA | 3.13 | 4.29 | 2.61 | 2.48 | 2.27 | 2.34 | 2.19 |
| EBITDA margin | +5.8% | +6.4% | +5.9% | +5.1% | +5.8% | +5.7% | +4.7% |
| Depreciation | 0.69 | 0.56 | 0.18 | 0.09 | 0.10 | 0.06 | 0.02 |
| Interest | 1.67 | 0.67 | 0.22 | 0.37 | 0.52 | 0.78 | 0.66 |
| Profit before tax | 3.12 | 3.57 | 2.63 | 2.36 | 1.83 | 1.66 | 1.53 |
| Tax | 0.93 | 1.01 | 0.72 | 0.67 | 0.52 | 0.46 | 0.42 |
| Net profit | 2.19 | 2.57 | 1.91 | 1.69 | 1.31 | 1.20 | 1.11 |
| Net profit margin | +4.0% | +3.8% | +4.3% | +3.5% | +3.3% | +2.9% | +2.4% |
| EPS (₹) | 2.18 | 2.57 | 1.90 | 1.70 | 4.04 | 3.68 | 3.44 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.00 | 10.00 | 10.00 | 10.00 | 3.25 | 3.25 | 3.25 |
| Reserves & surplus | 30.85 | 28.66 | 26.10 | 24.30 | 4.40 | 3.09 | 1.90 |
| Shareholders' funds (net worth) | 40.85 | 38.66 | 36.10 | 34.30 | 7.65 | 6.34 | 5.15 |
| Secured loans | 16.15 | 13.22 | 0.96 | 2.23 | 5.44 | 3.34 | 6.59 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.04 | 0.77 | 1.47 | 1.97 |
| Total debt | 16.15 | 13.22 | 0.96 | 2.27 | 6.21 | 4.81 | 8.56 |
| Total liabilities | 57.15 | 52.26 | 37.13 | 36.62 | 13.86 | 11.16 | 13.70 |
| Assets | |||||||
| Gross block | 3.24 | 5.41 | 0.80 | 0.76 | 0.40 | 0.34 | 0.15 |
| Net block | 1.53 | 4.39 | 0.34 | 0.47 | 0.20 | 0.25 | 0.12 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 12.42 | 7.19 | 4.20 | 4.20 | 4.20 | 4.35 | 3.57 |
| Inventories | 2.11 | 2.94 | 4.57 | 3.69 | 2.47 | 3.56 | 2.56 |
| Sundry debtors | 17.93 | 22.77 | 14.93 | 24.92 | 8.48 | 8.03 | 12.67 |
| Cash & bank balances | 2.16 | 1.42 | 2.41 | 4.95 | 1.29 | 0.12 | 0.14 |
| Loans & advances | 4.95 | 9.74 | 0.11 | 0.19 | 0.11 | 0.10 | 0.11 |
| Total current assets | 27.15 | 36.87 | 22.02 | 33.75 | 12.35 | 11.81 | 15.48 |
| Total current liabilities | 10.27 | 6.51 | 2.31 | 7.75 | 3.86 | 5.26 | 5.48 |
| Net working capital | 16.88 | 30.36 | 19.71 | 26.00 | 8.49 | 6.55 | 10.00 |
| Total assets | 57.15 | 52.26 | 37.13 | 36.62 | 13.86 | 11.16 | 13.70 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.42 | 2.41 | 4.95 | 1.29 | 0.12 | 0.14 | 1.15 |
| Net cash from operating activities | 15.43 | (6.78) | 5.73 | (11.95) | 1.10 | 5.44 | (6.55) |
| Net cash from investing activities | 8.25 | (4.78) | (6.65) | (5.02) | (0.80) | (0.94) | (3.68) |
| Net cash from financing activities | (22.94) | 10.57 | (1.63) | 20.63 | 0.87 | (4.51) | 9.22 |
| Net change in cash | 0.74 | (0.99) | (2.54) | 3.66 | 1.17 | (0.02) | (1.01) |
| Closing cash | 2.16 | 1.42 | 2.41 | 4.95 | 1.29 | 0.12 | 0.14 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -18.9% | +52.4% | -9.9% | +24.5% | -4.3% | -12.6% | - |
| EBITDA growth | -27.0% | +64.4% | +5.2% | +9.3% | -3.0% | +6.9% | - |
| PBT growth | -12.6% | +35.7% | +11.4% | +29.0% | +10.2% | +8.5% | +48.5% |
| Net income growth | -14.8% | +34.6% | +13.0% | +29.0% | +9.2% | +8.1% | - |
| Revenue CAGR (3Y) | +3.7% | +19.6% | +2.4% | +1.4% | +58.0% | - | +184.9% |
| EBITDA CAGR (3Y) | +8.1% | +23.6% | +3.7% | +4.2% | +49.5% | - | +215.1% |
| Profitability & leverage | |||||||
| Net income margin | +4.0% | +3.8% | +4.3% | +3.5% | +3.3% | +2.9% | +2.4% |
| Return on capital employed | - | +9.5% | +7.7% | +10.9% | +18.8% | +19.7% | +24.7% |
| Return on net worth | - | +6.9% | +5.4% | +8.1% | +18.7% | +20.9% | +24.4% |
| Debt / equity | - | 0.19 | 0.05 | 0.20 | 0.79 | 1.16 | 0.94 |
| Long-term debt / equity | - | 0.18 | 0.01 | 0.05 | 0.33 | 0.96 | 0.94 |
| Interest cover | 68.44 | 17.96 | 9.05 | 15.48 | 23.96 | 34.21 | 30.41 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 21.62 | 56.46 | 84.28 | 106.08 | 167.43 | 586.63 |
| Inventory turnover | - | 17.88 | 10.66 | 15.87 | 13.02 | 13.41 | 29.42 |
| Debtors turnover | - | 3.56 | 2.21 | 2.93 | 4.75 | 3.96 | 4.90 |
| EPS (₹) | 2.18 | 2.57 | 1.90 | 1.70 | 4.04 | 3.68 | 3.44 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 38.66 | 36.10 | 34.30 | 23.55 | 19.51 | 15.84 |
To see the full year-wise statements and ratios of Medico Intercontinental Limited, buy the company report.
Board of directors and KMP of Medico Intercontinental Limited
Medico Intercontinental Limited currently reports 6 directors and 2 key managerial personnel. 20 former directors have served the organization.
Current Directors and KMP
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Tanvi Samirbhai Shah | Director | 14 Aug 2018 | 8 Years 2 Months | Current |
| Samir Dilipkumar Shah Also directs: Azillian Healthcare Private Limited, Kings Marvela LLP, Ritz Formulations Private Limited and 5 more | Managing Director | 14 Aug 2018 | 8 Years 2 Months | Current |
| Ankur Amiram Dave Also directs: Azillian Healthcare Private Limited | Director | 23 Mar 2019 | 7 Years 7 Months | Current |
| Swati Jay Shah | Director | 29 May 2019 | 7 Years 4 Months | Current |
| Priyank Lalitbhai Sancheti | Director | 14 Nov 2022 | 3 Years 11 Months | Current |
| Dilipkumar Bhogilal Shah Also directs: Azillian Healthcare Private Limited, Kings Marvela LLP, Ritz Formulations Private Limited and 3 more | Ceo | 29 May 2019 | 7 Years 4 Months | Current |
Showing 6 of 8 current directors and KMP. View all directors and KMP
Peer comparison
Medico Intercontinental Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Visa Pharmaceuticals Private Limited | ₹98.08 Cr (FY 2016) | 34.0% | Kolkata, West Bengal, India | |||
| Inspira Bio-Pharm Private Limited | ₹97.29 Cr (FY 2025) | -17.0% | Mumbai, Maharashtra, India | |||
| Vea Impex (I) Private Limited | ₹96.93 Cr (FY 2025) | 16.0% | Mumbai, Maharashtra, India | |||
| Vitane Pharmaceuticals Private Limited | ₹96.05 Cr (FY 2025) | -3.0% | Thane, Maharashtra, India | |||
| Fulford (India) Private Limited | ₹95.86 Cr (FY 2025) | 50.0% | Mumbai, Maharashtra, India | |||
| Medico Intercontinental Limitedthis company | ₹84.08 Cr (FY 2026) | -₹3.21 Cr | -3.8% | -12.4% | 17 | Ahmedabad, Gujarat, India |
To see the full peer comparison of Medico Intercontinental Limited, buy the company report.
Auditor
Medico Intercontinental Limited is audited by V GOSWAMI & CO for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| V GOSWAMI & CO | FY 2023 | 0128769W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 58.50%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 41.50%.
Sep 2026
QUARTER
58.50% Promoters
41.50% Retail & Others
Promoter holding - history
Now 58.50% · Sep 2026High 58.50% · Sep 2026Low 55.20% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 58.50% | 57.20% | 57.20% | 55.20% |
| Public | 41.50% | 42.80% | 42.80% | 44.80% |
Charges & borrowings
Open charges
₹15.5 Cr
Satisfied charges
₹2.05 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 04 May 2019 | 100263610 | Standard Chartered Bank | ₹15.5 Cr | Open | |
| 02 Mar 2021 | 100439361 | Others | ₹1.05 Cr | Satisfied | |
| 06 Nov 2020 | 100384693 | Standard Chartered Bank | ₹1 Cr | Satisfied |
To see the full charge records of Medico Intercontinental Limited, buy the company report.
Total charge records: 3 View all charges
Deals & funding
Medico Intercontinental Limited has 69 deals on record (66 market trades, 2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹23.93 Cr; the latest was in June 2026.
Total deals
69
Market trades
66
Funding rounds
2
Secondary share transfer
1
Disclosed funding
₹23.93 Cr
Deals on record (5 of 69)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2024 | Market trade | ₹64 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited Seller: an individual |
| Mar 2024 | Market trade | ₹62.2 Lakh | Buyer: an individual Seller: Risi Finstock Private Limited |
| Mar 2022 | Market trade | ₹54.5 Lakh | Buyer: Swetsam Stock Holding Private Limited Seller: Silkon Trades LLP |
| Jan 2022 | Market trade | ₹69.7 Lakh | Buyer: VSL Securities Private Limited , an individual Seller: Shri Sanjay J Shah Huf, an individual |
| Jun 2021 | Market trade | ₹8.4 Lakh | Seller: Silkon Trades LLP |
To see the full deal history of Medico Intercontinental Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Medico Intercontinental Limited has 14 court cases on record: 13 filed by Medico Intercontinental, 1 filed against it. 4 cases are pending and 10 are disposed.
Total cases
14
Filed by the company
13
Filed against the company
1
Pending
4
Disposed
10
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 11 | 1 | 4 |
| High courts | 3 | 0 | 0 |
Cases on record (5 of 14)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, BENGALURU, Karnataka | Court case (Com.O.S.) | Filed against the company by Vetogen Animal Health LLP | Pending |
| High Court of Karnataka | Writ petition | Filed by the company against M/S. Vetogen Animal Health LLP | Disposed |
| District court, Ahmedabad, Gujarat | Court case (CR EN) | Filed by the company against Duram Pharmachem Pvt Ltd and 2 others | Disposed |
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed by the company against Duram Pharmachem Pvt Ltd and 2 others | Disposed |
| District court, Ahmedabad, Gujarat | Court case (SMST R) | Filed by the company against M/S. Medox Life Sciences | Pending |
To see the full case history of Medico Intercontinental Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Medico Intercontinental Limited has 18 MSME Form 1 returns on record between 2019 and 2024, listing 4,827 overdue payments to 81 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 81)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Medisky Pharmaceuticals Private Limited | |||
| an individual supplier | |||
| Innovative Healthcare | |||
| Regency Health Care | |||
| Nikvin Healthcare (India) Private Limited |
To see the full MSME payment records of Medico Intercontinental Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Medico Intercontinental has 4 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
4
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Sungrace Pharma Private Limited | U24110GJ2019PTC106267 | |
| Azillian Healthcare Private Limited | U24230GJ2005PTC047259 | |
| Ritz Formulations Private Limited | U24230GJ2019PTC106181 | |
| Evagrace Pharma Private Limited | U51909GJ2018PTC105415 |
To see the full group structure of Medico Intercontinental Limited, buy the company report.
Employees & EPFO
Medico Intercontinental Limited has a workforce of 17 employees on its EPFO records as of Sep 26, 2025, across 1 active EPFO establishment.
Employee count
17
Active EPFO establishments
1
Employee growth
-15%
GST
Medico Intercontinental has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAACI1860R1ZB | Gujarat | Active | 06 Nov 2018 |
To see the full GST registrations and return filing status of Medico Intercontinental Limited, buy the company report.
Recent activity
Medico Intercontinental Limited has 48 board changes on record since 1986: 28 appointments and 20 cessations. The latest: Parshwa Kaushal Shah was appointed as Director on 10 May 2024.
Filing
Medico Intercontinental Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
AGM
Medico Intercontinental Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge with Standard Chartered Bank of Rs. 15.50 Cr registered on 04 May 2019 with Charge ID 100263610 was modified on 30 Apr 2025.
Charges
A charge registered on 06 Nov 2020 via Charge ID 100384693 with Standard Chartered Bank was fully satisfied on 21 Nov 2024.
Appointed
Parshwa Kaushal Shah was appointed as Director.
Ceased
Nikul Dipakbhai Shah ceased to be Director.
Charges
A charge registered on 02 Mar 2021 via Charge ID 100439361 with Others was fully satisfied on 22 Apr 2024.
Appointed
Priyank Lalitbhai Sancheti was appointed as Director.
Ceased
Vijay Kumar Shah ceased to be Director.
Appointed
Nikul Dipakbhai Shah was appointed as Director.
Ceased
Hiren Ravindrabhai Shah ceased to be Director.
Charges
A charge with Others of Rs. 1.05 Cr registered on 02 Mar 2021 with Charge ID 100439361 was modified on 23 Jul 2021.
46 earlier events are in the company report.
Frequently asked questions
Medico Intercontinental is an active public limited company based in Ahmedabad, Gujarat, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 14 August 1984 (42+ years old) and is registered under CIN L24100GJ1984PLC111413. Listed on BSE: 539938.
Medico Intercontinental reported revenue of ₹84.08 Cr for FY 2025-26 (down 12.4% YoY) based on consolidated financials.
Medico Intercontinental has 8 current directors and KMP:
- Samir Dilipkumar Shah - Managing Director
- Tanvi Samirbhai Shah - Director
- Ankur Amiram Dave - Director
- Swati Jay Shah - Director
- Priyank Lalitbhai Sancheti - Director
- Parshwa Kaushal Shah - Director
- Dilipkumar Bhogilal Shah - Ceo
- Jay Sharadkumar Shah - Cfo
The latest financial statements of Medico Intercontinental on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Medico Intercontinental is 24AAACI1860R1ZB, registered in Gujarat. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Medico Intercontinental is L24100GJ1984PLC111413. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Medico Intercontinental is a listed company as per MCA records. Its shares are listed on BSE (code: 539938).
Medico Intercontinental has 14 court cases on record: 13 filed by the company and 1 filed against it. 4 are pending. Most are in the district courts.
Medico Intercontinental was incorporated on 14 August 1984, making it 42+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Medico Intercontinental has 69 deals on record (66 market trades, 2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹23.93 Cr; the latest was in June 2026.
The peers of Medico Intercontinental by revenue are Visa Pharmaceuticals Private Limited, Inspira Bio-Pharm Private Limited, Vea Impex (I) Private Limited, Vitane Pharmaceuticals Private Limited, Fulford (India) Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Parshwa Kaushal Shah was appointed as Director on 10 May 2024. Nikul Dipakbhai Shah ceased to be Director on 25 Apr 2024. Priyank Lalitbhai Sancheti was appointed as Director on 14 Nov 2022. Medico Intercontinental has 48 board changes on record in total.